Asthma with obesity: Preclinical study showed a reduction in the expression of NLRP3, activated caspase-1, and IL-1β in lung tissues, and suppression of AHR (128)COPD with obesity: Phase II study showed improvement in symptoms score, FVC and DLCO (150)Acute lung injury: Preclinical study showed the liraglutide can reduce the IL-1β and IL-18 levels in BAL fluid, and inhibit the expression of NLRP3 inflammasome (151). The gene discussed is NLRP3; the disease is obesity disorder.